When tetrahydropalmatine hydrochloride is wet-granulated for swine tablets, binder addition rate becomes the principal source of inter-batch dissolution drift

The hydrochloride salt of tetrahydropalmatine is incorporated at 5% w/w in a tablet core comprising microcrystalline cellulose PH102, lactose monohydrate, croscarmellose sodium 3% w/w, and colloidal silicon dioxide 0.5% w/w. Dry blending is conducted in a 200 L bin blender at 12 rpm for 15 minutes after a 1:10 geometric preblend of the API with lactose monohydrate. The binder solution is 5% w/w povidone K30 in purified water, added at a rate equivalent to 2% of dry powder mass per minute. Wet massing continues until power consumption on a 65 L high-shear granulator rises 8–10% above the dry-mix baseline; this endpoint is more reproducible than fixed-time granulation because the cohesive nature of the alkaloid shifts liquid distribution during the first 120 seconds. Granules are dried in a fluid-bed dryer at 55°C inlet air to a loss-on-drying of 2.0–3.5% per USP <731>. The dried granulate is passed through a 0.8 mm screen and compressed on a 16-station rotary tablet press with 8 mm round concave tooling. Compression force is adjusted until friability measured by USP <1216> remains ≤1.0% and disintegration by USP <701> is ≤15 minutes in water at 37°C. Content uniformity is evaluated by USP <905> at 10 individual tablet locations across the batch. Dissolution profiling is run in USP <711> Apparatus II at 50 rpm in 900 mL of 0.1 N hydrochloric acid at 37°C; acceptance thresholds are not established by a published veterinary monograph and are therefore derived from batch history and species-specific dose justification. The primary failure mode observed on pilot lines is cap-to-body lamination when residual granule moisture falls below 1.5% during extended hopper residence. This condition is mitigated by maintaining ambient relative humidity below 45% in the compression suite.

Sterile-filtration adsorption losses are quantified by passing a 10 mg/mL tetrahydropalmatine hydrochloride solution in 0.9% w/v sodium chloride through a 0.22 µm polyethersulfone membrane at a flow rate of 5 mL/min. The solution is buffered to pH 4.0–4.5 with citrate buffer because the free-base form exhibits limited aqueous solubility above pH 5.5. Filter adsorption is measured by UV absorbance at 280 nm before and after the first 50 mL of filtrate; discarding the initial filtrate volume is necessary when loss exceeds 2% of the assay value. Terminal steam sterilisation at 121°C for 15 minutes is evaluated only after pH-stability screening. Published degradation kinetics for tetrahydropalmatine hydrochloride in veterinary diluents are limited, so each formulation is tested by forced degradation at 40°C/75% RH and by isothermal exposure at 60°C for 10 days. If assay loss exceeds 3% under terminal load, aseptic filtration through a 0.22 µm double-sterilising-grade membrane in an isolator is selected. The filled vials are inspected for visible particulates per USP <790>, subvisible particulates per USP <788>, sterility per USP <71>, and bacterial endotoxins per USP <85>. The endotoxin limit is calculated from the maximum intended veterinary dose per species, not assigned as a fixed compendial value. Primary packaging is Type I borosilicate glass with a chlorobutyl rubber stopper; compatibility testing follows USP <381>. The main production bottleneck observed with this alkaloid is pH drift caused by carbon dioxide ingress during compounding, which can reduce solubility and increase filter-loading time if the vessel is not blanketed with nitrogen.

What limits content uniformity in low-dose companion-animal capsules of tetrahydropalmatine sulfate?

Veterinary capsule presentations containing tetrahydropalmatine sulfate are commonly prepared at 5 mg or 10 mg fill weight in size 3 hard gelatin capsules for companion animals. The principal content-uniformity constraint is the large difference between API and excipient particle size when the API has a D₉₀ above 100 µm. The sulfate salt is first milled through a 0.5 mm cone mill at a controlled feed rate to reduce agglomerates without generating excessive 10 µm fines. A 1:10 preblend with lactose monohydrate D₅₀ 80 µm is prepared in a 50 L drum blender operating at 15 rpm for 10 minutes. The preblend is then diluted with microcrystalline cellulose and 0.5% w/w magnesium stearate screened through a 600 µm sieve. Filling is performed on a dosator-type capsule machine at a fill weight of 150 mg; weight variation is monitored by sampling 20 capsules at 30-minute intervals. Blend uniformity and content uniformity are assessed by USP <905> acceptance value criteria, not by average assay alone. Dissolution of the capsule is run in USP <711> Apparatus II at 50 rpm in 900 mL of 0.1 N hydrochloric acid; shell cross-linking is excluded by adding pepsin when gelatin capsules show delayed rupture. The hygroscopic nature of the sulfate salt requires storage with silica gel desiccant and moisture testing by USP <921>. Batches that exceed 4.0% total moisture during storage exhibit shell deformation and cap separation on a 60,000 capsule/hr industrial line; this is a specific failure mode recorded during production transfer from pilot to commercial scale.

Dry blending of tetrahydropalmatine sulfate 2% w/w with anhydrous lactose and precipitated silica for oral powders is sensitive to electrostatic charge accumulation after 20 minutes of mixing in a 100 L V-blender without an intensifier bar. The API is pre-screened through a 150 µm stainless steel sieve to match the carrier particle size distribution and reduce segregation. Colloidal silicon dioxide at 0.5% w/w is added as a flow aid and charge suppressant. Blend sampling at 10 points across the blender shell is performed at the end of mixing, and assay relative standard deviation must remain ≤3.0% before filling. The powder is filled into aluminum foil laminate sachets under nitrogen to limit oxidative discolouration; foil seal integrity is tested by vacuum decay per ASTM F2338-09. Fill weight variation is monitored at 5-minute intervals throughout the filling campaign. The primary incompatibility observed with this formulation is moisture uptake above RH 60%, which converts the free-flowing powder into a sticky mass and causes blocking of the auger screw on a 40-station sachet machine. This operational boundary requires dehumidification of the filling suite to ≤40% RH and compression of the campaign into consecutive shifts to avoid overnight exposure. Residual solvent testing after drying follows VICH GL18; elemental impurities are screened according to ICH Q3D using inductively coupled plasma mass spectrometry. Published data for this specific sachet formulation of tetrahydropalmatine in veterinary species are limited, so stability-indicating assay and related substance methods are validated in-house before stability studies are initiated.

Granule growth kinetics in a high-shear mixer for oral granules loaded with tetrahydropalmatine hydrochloride

Oral granules for veterinary administration are produced by high-shear wet granulation of tetrahydropalmatine hydrochloride at 2% w/w on a lactose monohydrate and pregelatinized starch carrier. The dry mix is charged to a 65 L high-shear granulator; impeller speed is 150 rpm and chopper speed is 1500 rpm. Binder solution is 5% w/w povidone K30 in water, sprayed at 0.5 kg/min. Impeller power is recorded continuously, and the endpoint is taken when power increases 8–10% above the dry-mix baseline; torquemeter data are more reproducible than total wet massing time because raw material moisture shifts the liquid requirement by 1–2% batch to batch. Wet granules are dried in a fluid-bed dryer at 50°C inlet air to moisture ≤3.0% per USP <921>. The dried granulate is passed through a 0.8 mm screen; particles between 250 µm and 1000 µm are filled into polyethylene terephthalate/aluminum foil/paper laminate sachets. Fines below 250 µm are recycled at ≤10% of the new charge. Blend uniformity is tested at 10 locations after final blending; acceptance is 90–110% of label claim with RSD ≤5.0%. The granule form is selected because direct powder top dressing segregates during transport and generates dust that adheres to feeder hoppers; granule attrition during pneumatic transfer is measured by rotating drum test under ASTM D4058-96. A specific production failure observed during scale-up was cap formation on the granulator lid when the chopper was started before the impeller, causing localized overwetting and coarse granules above 1400 µm. The corrected start-up sequence begins with impeller only for 60 seconds before the chopper is engaged. Dissolution of the granule is assessed by USP <711> Apparatus II in 900 mL of 0.1 N hydrochloric acid at 50 rpm; release is not defined by a published veterinary monograph and is linked to batch history and species-specific bioavailability data.

A 10% w/w tetrahydropalmatine citrate stock solution in propylene glycol and water 1:1 v/v is diluted into drinking water lines for poultry. The stock solution is adjusted to pH 4.0–4.5 with citric acid because the citrate salt remains soluble under acidic conditions but can precipitate above pH 5.5. Dilution to a nominal 0.1 mg/mL final drinking water concentration is performed in high-density polyethylene tanks rather than galvanized steel reservoirs; dissolved zinc and iron ions can form insoluble complexes with the alkaloid and produce visible turbidity. Turbidity is measured by nephelometry per ISO 7027-1:2016 at 25°C; values above 5 NTU indicate precipitation or incompatibility with hard water with total alkalinity exceeding 180 mg/L calcium carbonate. The stock solution is protected from light in amber HDPE containers because photo-induced discoloration appears in transparent packaging under accelerated light exposure; this observation is confirmed by forced degradation testing per VICH GL3. Distribution lines are flushed after each medication cycle to remove residual film on inner walls; the cleaning protocol is validated by swab recovery of the API at 280 nm. The prepared drinking-water solution is assigned a maximum in-use storage interval of 24 hours at ambient temperature because published stability data for this specific veterinary configuration are limited and microbial growth risk increases beyond that period in non-sterile drinking water systems. Endpoint assay of the diluted solution is performed by HPLC; acceptance is set at 90–110% of the calculated concentration.

Feed premix homogeneity is maintained only when tetrahydropalmatine granules are introduced through a microdosing system at the mixer inlet

Medicated feed premixes are prepared at a concentration of 10% w/w tetrahydropalmatine hydrochloride on a wheat bran carrier. The API is first granulated with polyvinylpyrrolidone to reduce dust, then dried to ≤6.0% moisture and milled through a 1.0 mm screen before being blended with wheat bran in a 500 kg ribbon mixer. Batch homogeneity is sampled at 10 locations after 8 minutes of mixing; acceptance is 90–110% of the calculated premix concentration with RSD ≤5.0%. At the feed mill, the premix is metered into the main mixer using a microdosing system synchronized with the main feed flow; manual scoop addition at the mixer has produced localised assay spikes and is not permitted. Carryover is controlled by sequencing the medicated batch after a non-medicated flush batch and by validating the flush volume through assay of the first 100 kg of flush material. The specific problem of electrostatic separation between the light wheat bran carrier and the denser API granule is managed by adding 0.5% w/w food-grade mineral oil to the final premix; this addition also reduces dust during bag emptying. Release testing follows the matrix below.

Batch release is withheld until all listed tests meet the stated criteria; any failure requires a documented deviation and rework or rejection under 21 CFR 211.192.